KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Globus Medical (GMED) Cash & Equivalents (2016 - 2026)

Globus Medical filings provide 15 years of Cash & Equivalents readings, the most recent being $526.2 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 32.93% to $526.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $526.2 million, a 32.93% decrease, with the full-year FY2025 number at $526.2 million, down 32.93% from a year prior.
  • Cash & Equivalents hit $526.2 million in Q4 2025 for Globus Medical, up from $371.8 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $784.4 million in Q4 2024 to a low of $134.2 million in Q3 2022.
  • Median Cash & Equivalents over the past 5 years was $293.0 million (2023), compared with a mean of $335.3 million.
  • Biggest five-year swings in Cash & Equivalents: plummeted 62.91% in 2022 and later soared 210.56% in 2023.
  • Globus Medical's Cash & Equivalents stood at $193.1 million in 2021, then fell by 22.07% to $150.5 million in 2022, then soared by 210.56% to $467.3 million in 2023, then surged by 67.87% to $784.4 million in 2024, then crashed by 32.93% to $526.2 million in 2025.
  • The last three reported values for Cash & Equivalents were $526.2 million (Q4 2025), $371.8 million (Q3 2025), and $229.4 million (Q2 2025) per Business Quant data.